Agendia

AMSTERDAM and IRVINE, California, June 20, 2011 - - Not for release, distribution or publication in whole or in part, directly or indirectly, into or in the United States, Australia, Canada, OR Japan Agendia (or the "Company"), a commercial-stage molecular cancer diagnostics company, announces the postponement of its Initial Public Offering ("IPO") that was due to price today.

AMSTERDAM, The Netherlands, and IRVINE, California, June 9, 2011 - Agendia, a commercial-stage molecular cancer diagnostics company, announces today that it has entered into a research collaboration with The University of Texas MD Anderson Cancer Center, one of the world's leading cancer centers and whose research program is considered one of the most productive in the world aimed solely at cancer, and the Netherlands Cancer Institute (NKI) with the aim of improving diagnosis and treatment options of colorectal cancer patients.

AMSTERDAM, June 6, 2011 - - Agendia Publishes Prospectus and Sets Indicative IPO Price Range - Not for Release, Distribution or Publication in Whole or in Part, Directly or Indirectly, into or in The United States, Australia, Canada, or Japan This announcement is not a prospectus but an advertisement and nothing herein contains an offering of securities.

AMSTERAM and IRVINE, California, June 1, 2011 - Agendia, a commercial-stage molecular cancer diagnostics company, announces today that it will present results from four completed and one ongoing study, at the Annual Meeting of the American Society of Clinical Oncology (ASCO).